Author: admin

“B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market.

The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel B-Cell Non-Hodgkin Lymphoma treatment therapies with a considerable amount of success over the years. 

• B-Cell Non-Hodgkin Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-Cell Non-Hodgkin Lymphoma treatment 

• Emerging B-Cell Non-Hodgkin Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-Cell Non-Hodgkin Lymphoma market in the coming years.   

• In May 2024, Bristol Myers-Squibb stated that, TRANSCEND FL (NCT04245839) is a global, multicenter, open-label Phase 2 study evaluating the efficacy and safety of Breyanzi in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, including follicular lymphoma. The primary endpoint is the overall response rate, including the best overall response of complete or partial response as assessed by an Independent Review Committee. Secondary endpoints include complete response rate, duration of response, progression-free survival, and safety.

• In March 2023, Oncternal Therapeutics, Inc. has commenced a trial named “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.” This trial aims to evaluate Zilovertamab, an ROR1 Antibody, in combination with Ibrutinib versus Ibrutinib combined with a placebo in individuals diagnosed with Relapsed or Refractory Mantle Cell Lymphoma.

• In May 2023, Janssen Biotech, Inc., a branch of the Janssen Pharmaceutical Companies under Johnson & Johnson, has disclosed its global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG). The agreement aims to jointly develop, manufacture, and market advanced chimeric antigen receptor (CAR) T-cell therapies targeted for treating B-cell malignancies.

• In May 2023, Genmab A/S declared that the U.S. Food and Drug Administration (FDA) has granted approval for EPKINLY™ (epcoritamab-bysp) as the inaugural and sole T-cell engaging bispecific antibody designated for treating adult patients experiencing relapsed or refractory (R/R) diffuse large B-Cell Non-Hodgkin Lymphoma (DLBCL). This includes DLBCL not otherwise specified (NOS), encompassing cases originating from indolent lymphoma, and high-grade B-Cell Non-Hodgkin Lymphoma, following two or more lines of systemic therapy.

• In January 2023, Fate Therapeutics, Inc. disclosed their decision to reject a proposal from Janssen Biotech, Inc. (“Janssen”) regarding the continuation of their collaboration and option agreement under revised terms and conditions. Consequently, this refusal has led to the termination of the agreement, and all ongoing collaboration activities between the parties are scheduled to be concluded by the first quarter of 2023.

B-Cell Non-Hodgkin Lymphoma Overview

B-Cell Non-Hodgkin Lymphoma (B-Cell NHL) is a type of cancer that originates in the B-lymphocytes, a type of white blood cell crucial to the immune system. B-Cell NHL represents the most common form of Non-Hodgkin Lymphoma, accounting for about 85% of cases. It includes various subtypes, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma. Symptoms typically include painless swollen lymph nodes, fatigue, fever, night sweats, and unexplained weight loss. Treatments may involve chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation depending on the subtype and disease stage.

Get a Free Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight

Emerging B-Cell Non-Hodgkin Lymphoma Drugs Under Different Phases of Clinical Development Include:

• VIP 924: Vincerx Pharma

• UBX-303-1: Ubix Therapeutics

• BMF-219: Biomea Fusion Inc.

• SHR-A1912: Shanghai Hengrui Pharmaceutical

• Ociperlimab: BeiGene

• AUTO3: Autolus Limited

• GNC-038: SystImmune Inc

• Poseltinib: Hanmi Pharmaceutical

• Abexinostat: Xynomic Pharmaceuticals

• PF-07901801: Pfizer

• Odronextamab: ZAI Lab

• Zilovertamab: Oncternal Therapeutics

• PF-07901801: Pfizer

• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.     

• TG-1801: TG Therapeutics, Inc.

B-Cell Non-Hodgkin Lymphoma Route of Administration

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• intravenous

• Subcutaneous

• Topical.

B-Cell Non-Hodgkin Lymphoma Molecule Type

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment

• B-Cell Non-Hodgkin Lymphoma Assessment by Product Type

• B-Cell Non-Hodgkin Lymphoma By Stage and Product Type

• B-Cell Non-Hodgkin Lymphoma Assessment by Route of Administration

• B-Cell Non-Hodgkin Lymphoma By Stage and Route of Administration

• B-Cell Non-Hodgkin Lymphoma Assessment by Molecule Type

• B-Cell Non-Hodgkin Lymphoma by Stage and Molecule Type

DelveInsight’s B-Cell Non-Hodgkin Lymphoma Report covers around 170+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further B-Cell Non-Hodgkin Lymphoma product details are provided in the report. Download the B-Cell Non-Hodgkin Lymphoma pipeline report to learn more about the emerging B-Cell Non-Hodgkin Lymphoma therapies

Some of the key companies in the B-Cell Non-Hodgkin Lymphoma Therapeutics Market include:

Key companies developing therapies for B-Cell Non-Hodgkin Lymphoma are – Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.

B-Cell Non-Hodgkin Lymphoma Pipeline Analysis:

The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.

• B-Cell Non-Hodgkin Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about B-Cell Non-Hodgkin Lymphoma drugs and therapies

B-Cell Non-Hodgkin Lymphoma Pipeline Market Drivers

• Increase in prevalence of B-Cell Non-Hodgkin Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-Cell Non-Hodgkin Lymphoma Market.

B-Cell Non-Hodgkin Lymphoma Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-Cell Non-Hodgkin Lymphoma Market growth.

Scope of B-Cell Non-Hodgkin Lymphoma Pipeline Drug Insight    

• Coverage: Global

• Key B-Cell Non-Hodgkin Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others

• Key B-Cell Non-Hodgkin Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others

• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-Cell Non-Hodgkin Lymphoma current marketed and B-Cell Non-Hodgkin Lymphoma emerging therapies

• B-Cell Non-Hodgkin Lymphoma Market Dynamics: B-Cell Non-Hodgkin Lymphoma market drivers and B-Cell Non-Hodgkin Lymphoma market barriers 

Request for Sample PDF Report for B-Cell Non-Hodgkin Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. B-Cell Non-Hodgkin Lymphoma Report Introduction

2. B-Cell Non-Hodgkin Lymphoma Executive Summary

3. B-Cell Non-Hodgkin Lymphoma Overview

4. B-Cell Non-Hodgkin Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. B-Cell Non-Hodgkin Lymphoma Pipeline Therapeutics

6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase II/III)

7. B-Cell Non-Hodgkin Lymphoma Mid Stage Products (Phase II)

8. B-Cell Non-Hodgkin Lymphoma Early Stage Products (Phase I)

9. B-Cell Non-Hodgkin Lymphoma Preclinical Stage Products

10. B-Cell Non-Hodgkin Lymphoma Therapeutics Assessment

11. B-Cell Non-Hodgkin Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. B-Cell Non-Hodgkin Lymphoma Key Companies

14. B-Cell Non-Hodgkin Lymphoma Key Products

15. B-Cell Non-Hodgkin Lymphoma Unmet Needs

16 . B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers

17. B-Cell Non-Hodgkin Lymphoma Future Perspectives and Conclusion

18. B-Cell Non-Hodgkin Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus

“Non-Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer Market.

The Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Non-Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 

• Non-Small Cell Lung Cancer companies working in the treatment market are Merck Sharp & Dohme LLC, Qilu Pharmaceutical Co., Ltd., Merus N.V., Zymeworks BC Inc., AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment 

• Emerging Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others are expected to have a significant impact on the Non-Small Cell Lung Cancer market in the coming years. 

• In January 2024, Gilead Sciences announced that the Phase 3 EVOKE-01 study failed to achieve its primary endpoint of overall survival (OS) in patients with previously treated metastatic non-small cell lung cancer (NSCLC). The study compared Trodelvy (sacituzumab govitecan-hziy; SG) with docetaxel in patients with metastatic or advanced NSCLC who had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy.

• In February 2024, The FDA has granted breakthrough therapy designation to BAY 2927088, a new oral small molecule tyrosine kinase inhibitor (TKI), for the treatment of patients with unresectable or metastatic HER2-mutated non-small cell lung cancer (NSCLC).

• In June 2023, BioNTech SE announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial assessing their next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart). This trial is a key component of BioNTech’s plan to launch several pivotal trials in 2023 and 2024.

Non-Small Cell Lung Cancer Overview

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It typically grows and spreads more slowly than small cell lung cancer (SCLC). NSCLC includes several subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each originating from different types of lung cells. Risk factors include smoking, exposure to carcinogens, and genetic predispositions. Symptoms may include persistent cough, chest pain, and shortness of breath. NSCLC is often diagnosed through imaging and biopsy, with treatments ranging from surgery and radiation to targeted therapies and immunotherapy.

Get a Free Sample PDF Report to know more about Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight

Emerging Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• V940: Merck Sharp & Dohme LLC

• QL1706: Qilu Pharmaceutical Co., Ltd.

• Zenocutuzumab (MCLA-128): Merus N.V.

• ZW49: Zymeworks BC Inc.

• Ensartinib (X-396): Xcovery

• SAR408701: Sanofi

• Hyleukin-7 (NT-I7;Efineptakin Alfa): NeoImmune Tech

• Avelumab (Bavencio): Merck KGaA and Pfizer

• Sitravatinib: Mirati Therapeutics

• Trastuzumab deruxtecan: AstraZeneca

• DS-1062a: Daiichi Sankyo, Inc.

• Durvalumab: Parexel

• Sacituzumab Govitecan-hziy (SG): Gilead Sciences

• Pembrolizumab: Merck Sharp & Dohme LLC

• Domvanalimab: Arcus Biosciences, Inc.

• ONO-4538: Ono Pharmaceutical Co. Ltd

• M7824: EMD Serono

• Retifanlimab: Incyte Corporation

• Lenvatinib: Eisai Inc.

Non-Small Cell Lung Cancer Route of Administration

Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Non-Small Cell Lung Cancer Molecule Type

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

• Non-Small Cell Lung Cancer Assessment by Product Type

• Non-Small Cell Lung Cancer By Stage and Product Type

• Non-Small Cell Lung Cancer Assessment by Route of Administration

• Non-Small Cell Lung Cancer By Stage and Route of Administration

• Non-Small Cell Lung Cancer Assessment by Molecule Type

• Non-Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s Non-Small Cell Lung Cancer Report covers around 120+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Non-Small Cell Lung Cancer product details are provided in the report. Download the Non-Small Cell Lung Cancer pipeline report to learn more about the emerging Non-Small Cell Lung Cancer therapies

Some of the key companies in the Non-Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for Non-Small Cell Lung Cancer are – Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Sanofi, Astellas Pharma Inc., and others.

Non-Small Cell Lung Cancer Pipeline Analysis:

The Non-Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.

• Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Small Cell Lung Cancer drugs and therapies

Non-Small Cell Lung Cancer Pipeline Market Drivers

• Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market, the development of therapies targeting specific mutations are expected to dominate the upcoming market, are some of the important factors that are fueling the Non-Small Cell Lung Cancer Market.

Non-Small Cell Lung Cancer Pipeline Market Barriers

• However, Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast, and other factors are creating obstacles in the Non-Small Cell Lung Cancer Market growth.

Scope of Non-Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global

• Key Non-Small Cell Lung Cancer Companies: Merck Sharp & Dohme LLC, Qilu Pharmaceutical Co., Ltd., Merus N.V., Zymeworks BC Inc., AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Merck Sharp & Dohme LLC, Arcus Biosciences, Inc., Ono Pharmaceutical Co. Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others

• Key Non-Small Cell Lung Cancer Therapies: V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, Telisotuzumab Vedotin, Ensartinib (X-396), SAR408701, Hyleukin-7 (NT-I7;Efineptakin Alfa), Avelumab (Bavencio), Sitravatinib, Trastuzumab deruxtecan, DS-1062a, Durvalumab, Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Domvanalimab, ONO-4538, M7824, Retifanlimab, Lenvatinib, and others

• Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies

• Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Non-Small Cell Lung Cancer Report Introduction

2. Non-Small Cell Lung Cancer Executive Summary

3. Non-Small Cell Lung Cancer Overview

4. Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. Non-Small Cell Lung Cancer Pipeline Therapeutics

6. Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. Non-Small Cell Lung Cancer Mid Stage Products (Phase II)

8. Non-Small Cell Lung Cancer Early Stage Products (Phase I)

9. Non-Small Cell Lung Cancer Preclinical Stage Products

10. Non-Small Cell Lung Cancer Therapeutics Assessment

11. Non-Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Small Cell Lung Cancer Key Companies

14. Non-Small Cell Lung Cancer Key Products

15. Non-Small Cell Lung Cancer Unmet Needs

16 . Non-Small Cell Lung Cancer Market Drivers and Barriers

17. Non-Small Cell Lung Cancer Future Perspectives and Conclusion

18. Non-Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline Dynamics 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck Sharp

“Tenosynovial Giant Cell Tumors Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tenosynovial Giant Cell Tumors Market.

The Tenosynovial Giant Cell Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Tenosynovial Giant Cell Tumors Pipeline Report:

• Companies across the globe are diligently working toward developing novel Tenosynovial Giant Cell Tumors treatment therapies with a considerable amount of success over the years. 

• Tenosynovial Giant Cell Tumors companies working in the treatment market are Deciphera Pharmaceuticals, Elixiron Immunotherapeutics, Daiichi Sankyo Co., Ltd., Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others, are developing therapies for the Tenosynovial Giant Cell Tumors treatment 

• Emerging Tenosynovial Giant Cell Tumors therapies in the different phases of clinical trials are- Vimseltinib, EI-1071, Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others are expected to have a significant impact on the Tenosynovial Giant Cell Tumors market in the coming years.   

• In August 2024, Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President: Toichi Takino) announced that the U.S. Food and Drug Administration (FDA) has accepted a priority review for vimseltinib, a colony stimulating factor 1 receptor (CSF1R) inhibitor, for treating patients with tenosynovial giant cell tumor (TGCT). The New Drug Application (NDA) was submitted on August 14, 2023, and Deciphera Pharmaceuticals, a wholly-owned subsidiary of Ono, is developing the drug. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of February 17, 2025. In mid-July, the European Medicines Agency (EMA) also accepted vimseltinib’s Marketing Authorization Application (MAA), beginning the centralized review process.

• In July 2024, The European Medicines Agency (EMA) has accepted Deciphera Pharmaceuticals, a subsidiary of Ono Pharmaceutical, for the review of their marketing authorization application (MAA) for vimseltinib, aimed at treating tenosynovial giant cell tumor (TGCT). Vimseltinib is a colony-stimulating factor 1 receptor (CSF1R) inhibitor.

Tenosynovial Giant Cell Tumors Overview 

Tenosynovial Giant Cell Tumors (TGCT) are rare, benign tumors that occur in the synovial lining of joints, tendons, or bursae. These tumors can be locally aggressive, leading to pain, swelling, and reduced mobility in the affected area, often impacting the knee, hip, or hand. TGCT is divided into two types: localized (often found in tendons) and diffuse (which can involve entire joints). While typically non-cancerous, they can cause significant joint damage if left untreated. Treatment options include surgery, radiation, and emerging targeted therapies like CSF1R inhibitors.

Get a Free Sample PDF Report to know more about Tenosynovial Giant Cell Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight

Emerging Tenosynovial Giant Cell Tumors Drugs Under Different Phases of Clinical Development Include:

• Vimseltinib: Deciphera Pharmaceuticals

• EI-1071: Elixiron Immunotherapeutics

• Pexidartinib: Daiichi Sankyo Co., Ltd.

• vimseltinib: Deciphera Pharmaceuticals

• Pimicotinib(ABSK021): Abbisko Therapeutics

• AMB-05X: AmMax Bio, Inc.

• Emactuzumab: SynOx Therapeutics Limited

• Pimicotinib(ABSK021): Abbisko Therapeutics

• FPA008: Five Prime Therapeutics

• MCS110: Novartis

Tenosynovial Giant Cell Tumors Route of Administration

Tenosynovial Giant Cell Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Tenosynovial Giant Cell Tumors Molecule Type

Tenosynovial Giant Cell Tumors Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Tenosynovial Giant Cell Tumors Pipeline Therapeutics Assessment

• Tenosynovial Giant Cell Tumors Assessment by Product Type

• Tenosynovial Giant Cell Tumors By Stage and Product Type

• Tenosynovial Giant Cell Tumors Assessment by Route of Administration

• Tenosynovial Giant Cell Tumors By Stage and Route of Administration

• Tenosynovial Giant Cell Tumors Assessment by Molecule Type

• Tenosynovial Giant Cell Tumors by Stage and Molecule Type

DelveInsight’s Tenosynovial Giant Cell Tumors Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Tenosynovial Giant Cell Tumors product details are provided in the report. Download the Tenosynovial Giant Cell Tumors pipeline report to learn more about the emerging Tenosynovial Giant Cell Tumors therapies

Some of the key companies in the Tenosynovial Giant Cell Tumors Therapeutics Market include:

Key companies developing therapies for Tenosynovial Giant Cell Tumors are – Elixiron Immunotherapeutics, AmMax Bio, Inc., Deciphera Pharmaceuticals, Novartis Oncology, and others.

Tenosynovial Giant Cell Tumors Pipeline Analysis:

The Tenosynovial Giant Cell Tumors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Tenosynovial Giant Cell Tumors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tenosynovial Giant Cell Tumors Treatment.

• Tenosynovial Giant Cell Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Tenosynovial Giant Cell Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tenosynovial Giant Cell Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tenosynovial Giant Cell Tumors drugs and therapies

Tenosynovial Giant Cell Tumors Pipeline Market Drivers

• Increasing Prevalence, Advances in Targeted Therapies, Ongoing Clinical Trials, Growing Investment in Research, Rising Awareness, are some of the important factors that are fueling the Tenosynovial Giant Cell Tumors Market.

Tenosynovial Giant Cell Tumors Pipeline Market Barriers

• However, High Treatment Costs, Limited Approved Therapies, Adverse Side Effects, Delayed Diagnosis, and other factors are creating obstacles in the Tenosynovial Giant Cell Tumors Market growth.

Scope of Tenosynovial Giant Cell Tumors Pipeline Drug Insight    

• Coverage: Global

• Key Tenosynovial Giant Cell Tumors Companies: Deciphera Pharmaceuticals, Elixiron Immunotherapeutics, Daiichi Sankyo Co., Ltd., Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others

• Key Tenosynovial Giant Cell Tumors Therapies: Vimseltinib, EI-1071, Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others

• Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies

• Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers 

Request for Sample PDF Report for Tenosynovial Giant Cell Tumors Pipeline Assessment and clinical trials

Table of Contents

1. Tenosynovial Giant Cell Tumors Report Introduction

2. Tenosynovial Giant Cell Tumors Executive Summary

3. Tenosynovial Giant Cell Tumors Overview

4. Tenosynovial Giant Cell Tumors- Analytical Perspective In-depth Commercial Assessment

5. Tenosynovial Giant Cell Tumors Pipeline Therapeutics

6. Tenosynovial Giant Cell Tumors Late Stage Products (Phase II/III)

7. Tenosynovial Giant Cell Tumors Mid Stage Products (Phase II)

8. Tenosynovial Giant Cell Tumors Early Stage Products (Phase I)

9. Tenosynovial Giant Cell Tumors Preclinical Stage Products

10. Tenosynovial Giant Cell Tumors Therapeutics Assessment

11. Tenosynovial Giant Cell Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Tenosynovial Giant Cell Tumors Key Companies

14. Tenosynovial Giant Cell Tumors Key Products

15. Tenosynovial Giant Cell Tumors Unmet Needs

16 . Tenosynovial Giant Cell Tumors Market Drivers and Barriers

17. Tenosynovial Giant Cell Tumors Future Perspectives and Conclusion

18. Tenosynovial Giant Cell Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tenosynovial Giant Cell Tumors Pipeline Insights and Analysis 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | Deciphera Pharma, Elixiron Immunotherapeutics, Daiichi Sankyo, Abbisko Thera

DelveInsight’s “Open Angle Glaucoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Open Angle Glaucoma, historical and forecasted epidemiology as well as the Open Angle Glaucoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Open Angle Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Open Angle Glaucoma Market Forecast

Some of the key facts of the Open Angle Glaucoma Market Report: 

• The Open Angle Glaucoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In the 7MM, there were 17,280,267 cases of glaucoma overall in 2022. During the projected period (2023–2032), this number is expected to rise at a significant CAGR

• In the 7MM, there were 7,322,693 cases of diagnosed prevalent glaucoma in 2022. During the study period (2019–2032), there is predicted to be a considerable compound annual growth rate (CAGR) of these cases

• With 2,251,283 cases estimated to be the highest diagnosed prevalence of Open Angle Glaucoma (OAG) in the US in 2022, it is anticipated that this number will rise sharply in the near future as a result of improving diagnostic tests and population growth.

• With 649,908 cases of Open Angle Glaucoma (OAG), Germany had the most diagnosed prevalent population of any European nation in 2022. France came in second with 631,650 cases. However, out of the 7MM, Spain had the least number of people with a diagnosis

• There are numerous medications in the Open Angle Glaucoma pipeline at the moment. Among the most prominent medications for this indication are iDoseTR, NCX 470, PDP-716, AGN-193408, and a few more. Current clinical studies and ongoing research could alter the industry

• Key Open Angle Glaucoma Companies: OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others

• Key Open Angle Glaucoma Therapies: Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others

• The Open Angle Glaucoma epidemiology based on gender analyzed that women are predominantly affected by Open Angle Glaucoma (OAG) in the 7MM

• The Open Angle Glaucoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Open Angle Glaucoma pipeline products will significantly revolutionize the Open Angle Glaucoma market dynamics.

Open Angle Glaucoma Overview

If ignored, open-angle glaucoma (OAG), a common and dangerous eye ailment that damages the optic nerve, can result in blindness or visual loss. It is the most common type of glaucoma and usually progresses slowly over time, frequently with no symptoms at first. For this reason, it is also called the “silent thief of sight.”

Get a Free sample for the Open Angle Glaucoma Market Report 

https://www.delveinsight.com/report-store/open-angle-glaucoma-market

Open Angle Glaucoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Open Angle Glaucoma Epidemiology Segmentation:

The Open Angle Glaucoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalent Cases of Glaucoma in the 7MM

• Total Diagnosed Prevalent Cases Glaucoma in the 7MM

• Type-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM

• Type-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM 

• Gender-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM

• Age-specific Diagnosed Prevalent Cases of Open Angle Glaucoma (OAG) in the 7MM

Download the report to understand which factors are driving Open Angle Glaucoma epidemiology trends @ Open Angle Glaucoma Epidemiology Forecast

Open Angle Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Open Angle Glaucoma market or expected to get launched during the study period. The analysis covers Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Open Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Open Angle Glaucoma Therapies and Key Companies

• NCX-470: Nicox Ophthalmics

• PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma

• TC-002 (latanoprost): TearClear

• iDose TR (Travoprost Intraocular Implant): Glaukos Corporation

• Sepetaprost/DE-126/ONO-9054/STN-1012600: Santen Inc/Ono Pharmaceutical

• Catioprost/DE-130A/STN1013001: Santen Pharmaceuticals

• Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain

• H-1337: D. Western Therapeutics Institute (DWTI)

• OTX-TIC: Ocular Therapeutix, Inc.

• LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)

• TRS01: Tarsier Pharma

• POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic

• Nyxol (Phentolamine Mesylate): Ocuphire Pharma

• QLS-101: Qlaris Bio, Inc.

• BTQ-1902: Betaliq, Inc.

• VVN539: VivaVision Biotech, Inc.

• AGN-193408: Abbvie

Discover more about therapies set to grab major Open Angle Glaucoma market share @ Open Angle Glaucoma Treatment Market

Open Angle Glaucoma Market Strengths

• Rising prevalence of Open Angle Glaucoma (OAG) resulting in demand for improved treatments. Growing awareness about the importance of early detection to reduce the disease burden contributes to increased screening and diagnosis rates

Open Angle Glaucoma Market Opportunities

• With increasing awareness and improving healthcare infrastructure, the Open Angle Glaucoma (OAG) market has growth potential in emerging markets

Scope of the Open Angle Glaucoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Open Angle Glaucoma Companies: OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others

• Key Open Angle Glaucoma Therapies: Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others

• Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies

• Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Open Angle Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Open Angle Glaucoma Market Access and Reimbursement 

To know more about Open Angle Glaucoma companies working in the treatment market, visit @ Open Angle Glaucoma Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Open Angle Glaucoma Market Report Introduction

2. Executive Summary for Open Angle Glaucoma

3. SWOT analysis of Open Angle Glaucoma

4. Open Angle Glaucoma Patient Share (%) Overview at a Glance

5. Open Angle Glaucoma Market Overview at a Glance

6. Open Angle Glaucoma Disease Background and Overview

7. Open Angle Glaucoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Open Angle Glaucoma 

9. Open Angle Glaucoma Current Treatment and Medical Practices

10. Open Angle Glaucoma Unmet Needs

11. Open Angle Glaucoma Emerging Therapies

12. Open Angle Glaucoma Market Outlook

13. Country-Wise Open Angle Glaucoma Market Analysis (2019–2032)

14. Open Angle Glaucoma Market Access and Reimbursement of Therapies

15. Open Angle Glaucoma Market Drivers

16. Open Angle Glaucoma Market Barriers

17.  Open Angle Glaucoma Appendix

18. Open Angle Glaucoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Open Angle Glaucoma Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc.